Biocon Ltd

Stage 3 · Topping · week 5

As of 9 Oct 2026, Biocon is in Stage 3 — topping, where an uptrend loses steam, in week 5 (since 8 Sep 2026). It closed at ₹349, 20.7% below its 52-week high and below its 200-day average, which is falling. In Health Care, 44.6% of stocks are in Stage 2.

Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. More about the company

₹349.4
-0.17% today
₹57,223 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dBiotechnology 22.2%-11.1 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is BIOCON early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-20.7%
₹340.1 lo₹440.7 hi
20.7% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 5
1w13w26w
Week 5 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-11.4%
200 DMA: ₹394.3 · sloping down
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.58x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -4.4% vs MA50 -4.7%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-10.9%
3M
-16.5%
6M
-0.1%
YTD
-13.0%
1Y
+0.9%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
Sector has 74 Stage 2 leaders. See Health Care Stage 2 →
Industry
Biotechnology
↓ Peaking
Stage 2%
22.2%
20d Δ
-11.1pp
1M return
-8.7%
3M return
-0.7%
Industry Stage-2 % · last 20 days
Industry has 2 Stage 2 leaders. See Biotechnology Stage 2 →
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 25w
S2 16w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S2 12w → S3 7w → S4 5w → S1 1w → S2 11w → S3 4w → S2 25w → S3 10w → S2 8w → S3 4w → S4 9w → S1 6w → S2 11w → S3 7w → S2 11w → S3 10w → S4 5w → S2 16w → S3 5w current
Total tracked: 168 weeks across 20 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-05-20
6 appearances in last 60 days. First seen: 2024-01-15.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S3
Wk 5 · Vol 0.58x
2026-10-08S3
Wk 5 · Vol 0.65x
2026-10-07S3
Wk 4 · Vol 1.37x
2026-10-06S3
Wk 4 · Vol 1.46x
2026-10-05S3
Wk 4 · Vol 0.66x
2026-10-01S3
Wk 4 · Vol 0.76x
2026-09-30S3
Wk 4 · Vol 0.55x
2026-09-29S3
Wk 3 · Vol 0.83x
2026-09-28S3
Wk 3 · Vol 0.64x
2026-09-25S3
Wk 3 · Vol 0.75x
2026-09-24S3
Wk 3 · Vol 0.45x
2026-09-23S3
Wk 3 · Vol 0.58x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹399.7
200 DMA
₹394.3
52W High
₹440.7
52W Low
₹340.1
5D Low
₹349.4
Resistance levels (recent highs)
20d High
₹395.2
60d High
₹440.7
120d High
₹440.7
250d High
₹440.7
Next resistance
+13.1%
to 20d High
Ask the Market AI about BIOCONAsk →
P/E (TTM)
152.7
Forward 36.4
Earnings Growth (YoY)
-72.5%
Revenue +2.3%
ROE
+1.1%
Profit margin +2.3%
Dividend Yield
0.11%
P/B 2.0
About this companyHealth Care· Biotechnology

Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.